8-K

                     SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C. 20549

                                FORM 8-K

                              CURRENT REPORT

                  PURSUANT TO SECTION 13 OR 15(d) OF THE
                     SECURITIES EXCHANGE ACT OF 1934

    Date of report (Date of earliest event reported): May 26, 2010

                            TECHNE CORPORATION
             (Exact Name of Registrant as Specified in Charter)


       Minnesota                     0-17272             41-1427402
(State or Other Jurisdiction       (Commission         I.R.S. Employer
of Incorporation)                  File Number)      Identification No.)

                614 Mckinley Place NE
                   Minneapolis, MN                       55413
       (Address of Principal Executive Offices)       (Zip Code)

     Registrant's telephone number, including area code:  (612) 379-8854

                              Not Applicable
      (Former Name or Former Address, if changed since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under any
of the following provisions:

/ /   Written communications pursuant to Rule 425 under the Securities Act
      17 CFR 230.425)

/ /   Soliciting material pursuant to Rule 14a-12 under the Exchange Act
      (17 CFR 240.14a-12)

/ /   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

/ /   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))










Item 5.02  Departure of Directors or Principal Officers; Election of
Directors; Appointment of Principal Officers

Effective May 26, 2010, Dr. Roeland Nusse was elected to the Board of
Directors of Techne Corporation (the "Company") and to the Nominations and
Governance Committee of the Board.  In connection with his service on the
Company's Board and Committee, Dr. Nusse will receive annual cash
compensation and stock options pursuant to the Company's director
compensation policy.

Dr. Nusse was not named as director pursuant to any arrangement or
understanding with any third person.  There is not currently, nor has there
been in the past, any material transactions with the Company or any of its
subsidiaries or affiliates in which Dr. Nusse has or had a direct or an
indirect material interest.

On May 26, 2010, the Company issued a press release announcing the
election of Dr. Nusse to the Company's Board of Directors.  The press
release is attached as Exhibit 99.1 and is incorporated by reference herein.



Item 9.01 Financial Statements and Exhibits

     (d) Exhibits

          99.1 Press Release dated May 26, 2010.


                            SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Dated: May 26, 2010                   TECHNE CORPORATION

                                      By: /s/ Thomas E. Oland
                                      ---------------------------
                                      Name: Thomas E. Oland
                                      Title: President and Chief
                                        Executive Officer




                          EXHIBIT INDEX

    Exhibit No. Description
    ----------- -----------
       99.1     Press release of Techne Corporation dated May 26, 2010.

EX-99.1

           TECHNE CORPORATION ANNOUNCES THAT DR. ROELAND NUSSE
              HAS ACCEPTED A SEAT ON ITS BOARD OF DIRECTORS

Minneapolis/May 26, 2010/--Techne Corporation (NASDAQ: TECH) today announced
that Roeland Nusse, Ph.D. has accepted a position on the Techne Corporation
Board of Directors and will also serve as a member of Techne's Nominations
and Governance Committee.  Dr. Nusse's initial term will begin immediately
and run through October 28, 2010.  Techne Corporation's shareholders reelect
all Directors on an annual basis.

Dr. Nusse has been a professor or associate professor in the Department of
Developmental Biology at Stanford University and an investigator at the
Howard Hughes Medical Institute since 1990. He has also been the chair of the
Department of Developmental Biology at Stanford since 2007.  His studies
involve the activity of proteins that determine cell fate during
embryogenesis. His lab has also used purified proteins to manipulate the
behavior of stem cells in culture, in particular neural stem cells.

Dr. Nusse was previously at the Netherlands Cancer Institute (Amsterdam, The
Netherlands) as a staff scientist and ultimately head of the Department of
Molecular Biology. Dr. Nusse earned a bachelor's degree in biology in 1975
from the University of Amsterdam and a doctorate in molecular biology from
the Netherlands Cancer Institute in 1980. He did his postdoctoral fellowship
at the University of California, San Francisco.

Dr. Nusse was elected to the prestigious National Academy of Sciences, a
private organization of scientists and engineers dedicated to the furtherance
of science and its use for the general welfare, at the Academy's 147th annual
meeting in April 2010.  Dr. Nusse was previously named a member of the
European Molecular Biology Organization in 1988, a member of the Royal Dutch
Academy of Sciences in 1997 and a member of the American Academy of Arts and
Sciences in 2001.

Mr. Thomas E. Oland, Techne Corporation's Chairman and CEO, said "I am
extremely pleased that Dr. Nusse has accepted a position on our Board of
Directors.  Dr. Nusse is an esteemed scientist and his background and
experience will be invaluable during the Board's strategic discussions.  He
will also serve as another strong mentor for the Company's senior scientific
staff. We are very fortunate to have a person of his caliber on our Board.  I
am very confident that he will make a significant contribution to our future
success."

                       *  *  *  *  *  *  *  *  *  *  *  *

Techne Corporation has two operating subsidiaries:  Research and Diagnostic
Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe,
Ltd. (R&D Europe) of Abingdon, England.  R&D Systems is a specialty
manufacturer of biological products.  R&D Systems has two subsidiaries,
BiosPacific, Inc. (BiosPacific), located in Emeryville, California and R&D
Systems China Co. Ltd., (R&D China), located in Shanghai, China.  BiosPacific
is a worldwide supplier of biologics to manufacturers of in vitro diagnostic
systems and immunodiagnostic kits. R&D China and R&D Europe distribute
biotechnology products.

Contact:  Greg Melsen, Chief Financial Officer
          Kathy Backes, Controller
          (612) 379-8854